59.94 0.00 (0.00%)
After hours: 4:57PM EST
|Bid||48.26 x 800|
|Ask||60.27 x 900|
|Day's Range||59.00 - 62.22|
|52 Week Range||26.00 - 65.48|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.00|
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Stocks with market capitalization between $2B and $10B, such as Allakos Inc (NASDAQ:ALLK) with a size of US$2.3b, do not attract as much attention from the investing community as do Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif., Nov. 08, 2018 -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the.
SAN CARLOS, Calif., Oct. 08, 2018 -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil.
Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO at $18 per share. The Analysts ...